Teachers Retirement System of The State of Kentucky Acquires 5,920 Shares of Five Prime Therapeutics, Inc. (FPRX)

Teachers Retirement System of The State of Kentucky grew its holdings in shares of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) by 24.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 29,872 shares of the biotechnology company’s stock after buying an additional 5,920 shares during the quarter. Teachers Retirement System of The State of Kentucky owned 0.11% of Five Prime Therapeutics worth $899,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Renaissance Technologies LLC bought a new position in Five Prime Therapeutics during the 1st quarter valued at about $16,734,000. State Street Corp grew its holdings in Five Prime Therapeutics by 25.7% during the 1st quarter. State Street Corp now owns 1,249,520 shares of the biotechnology company’s stock valued at $45,175,000 after purchasing an additional 255,488 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Five Prime Therapeutics by 162.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 298,395 shares of the biotechnology company’s stock valued at $8,984,000 after purchasing an additional 184,888 shares during the last quarter. Artal Group S.A. bought a new position in Five Prime Therapeutics during the 2nd quarter valued at about $4,517,000. Finally, Victory Capital Management Inc. grew its holdings in Five Prime Therapeutics by 28.9% during the 2nd quarter. Victory Capital Management Inc. now owns 666,440 shares of the biotechnology company’s stock valued at $20,066,000 after purchasing an additional 149,340 shares during the last quarter. Hedge funds and other institutional investors own 84.05% of the company’s stock.

Several brokerages recently commented on FPRX. Zacks Investment Research downgraded shares of Five Prime Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday. BMO Capital Markets reiterated a “hold” rating and set a $39.00 price target on shares of Five Prime Therapeutics in a report on Friday, September 22nd. Royal Bank Of Canada began coverage on shares of Five Prime Therapeutics in a report on Thursday, September 14th. They set an “outperform” rating and a $41.00 price target on the stock. Jefferies Group LLC reiterated a “buy” rating and set a $52.00 price target on shares of Five Prime Therapeutics in a report on Tuesday, September 12th. Finally, ValuEngine upgraded shares of Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $57.50.

WARNING: “Teachers Retirement System of The State of Kentucky Acquires 5,920 Shares of Five Prime Therapeutics, Inc. (FPRX)” was published by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.com-unik.info/2017/10/12/teachers-retirement-system-of-the-state-of-kentucky-acquires-5920-shares-of-five-prime-therapeutics-inc-fprx.html.

Five Prime Therapeutics, Inc. (NASDAQ FPRX) opened at 40.97 on Thursday. The firm has a 50-day moving average of $35.57 and a 200-day moving average of $31.91. Five Prime Therapeutics, Inc. has a 52 week low of $25.97 and a 52 week high of $60.98. The company’s market capitalization is $1.15 billion.

Five Prime Therapeutics (NASDAQ:FPRX) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($1.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.43). Five Prime Therapeutics had a negative net margin of 356.39% and a negative return on equity of 31.78%. The company had revenue of $7.80 million for the quarter, compared to analyst estimates of $8.32 million. During the same quarter in the prior year, the business earned ($0.49) earnings per share. Five Prime Therapeutics’s revenue was down 16.1% on a year-over-year basis. Analysts anticipate that Five Prime Therapeutics, Inc. will post ($5.29) EPS for the current fiscal year.

In other Five Prime Therapeutics news, Director William R. Ringo sold 1,800 shares of Five Prime Therapeutics stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $40.26, for a total transaction of $72,468.00. Following the completion of the sale, the director now directly owns 1,200 shares in the company, valued at $48,312. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director William R. Ringo sold 2,000 shares of Five Prime Therapeutics stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $38.00, for a total transaction of $76,000.00. Following the sale, the director now owns 2,000 shares of the company’s stock, valued at $76,000. The disclosure for this sale can be found here. 6.50% of the stock is owned by company insiders.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Want to see what other hedge funds are holding FPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Five Prime Therapeutics, Inc. (NASDAQ:FPRX).

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

What are top analysts saying about Five Prime Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Five Prime Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit